Fragment based drug discovery is a process that uses small molecules known as fragments to develop potential drug candidates. Fragments have a lower molecular weight than traditional drug molecules and have a higher chance of binding to target proteins. This process involves screening an existing chemical library or developing a new library of fragments, identifying potential binders through biophysical techniques, optimizing and growing the fragments to develop drug-like candidates. The global fragment based drug discovery market is witnessing lucrative growth opportunities owing to increasing incidence of chronic diseases like cancer and rise in research outsourcing activities by major pharmaceutical companies.
The Global Fragment Based Drug Discovery Market is estimated to be valued at USD 1.21 Bn in 2024 and is expected to reach USD 2.60 Bn by 2031, growing at a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031.
Growing demand for new drugs:
The rising prevalence of chronic diseases and need for improved treatment options is expected to propel the demand for Global Fragment Based Drug Discovery Market services over the forecast period. Several pharmaceutical companies are outsourcing drug discovery research to maximize productivity and bring new drugs to market faster.
The growing complexity of disease pathology, drug designers are increasingly relying on fragment based drug discovery approaches to efficiently identify novel starting points for drug design. This technique helps pharmaceutical companies to optimize hit identification and reduce development costs by eliminating non-viable candidates at an early stage.
Get More Insights - Global Fragment Based Drug Discovery Market
Get this Report in Japanese Language: 世界のフラグメントベース創薬市場
Get this Report in Korean Language: 글로벌 단편 기반 약물 발견 시장
Explore More Related Topics On -Global Ultrasonic Nebulizer Industry - An Overview